Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting - Wikidata - awgldk - TriplyDB

Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting

Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting

http://www.wikidata.org/entity/Q28191931

about

sameAs

Antiplatelet agents for intermittent claudication Managing Antiplatelet Therapy and Anticoagulants in Patients with Coronary Artery Disease and Atrial Fibrillation Clopidogrel's role in the management of atherosclerotic disease: a focus on acute coronary syndromes The role of antiplatelet therapy in the management of acute coronary syndromes Stent thrombosis in patients treated with thienopyridines: clinical description of 10 cases Role of abciximab in the treatment of coronary artery disease The safety and efficacy of aspirin and clopidogrel as a combination treatment in patients with coronary heart disease Oral antiplatelet therapy and percutaneous coronary intervention Clopidogrel in the treatment of ischaemic heart disease Antiplatelet therapy in peripheral occlusive arterial disease Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology Effect of atorvastatin and clopidogrel co-administration after coronary stenting in korean patients with stable angina.Aspirin and platelet adenosine diphosphate receptor antagonists in acute coronary syndromes and percutaneous coronary intervention: role in therapy and strategies to overcome resistance.Is routine stenting for acute myocardial infarction superior to balloon angioplasty? A randomised comparison in a large cohort of unselected patients.Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Changing roles of anticoagulant and antiplatelet treatment during percutaneous coronary intervention.Risk:benefit assessment of old medicines.Clopidogrel resistance response in patients with coronary artery disease and metabolic syndrome: the role of hyperglycemia and obesity.Bisphosphonates as anti-inflammatory agents in ankylosing spondylitis and spondylarthropathies.Efficacy and safety of different doses of tirofiban combined with ticagrelor on diabetic patients with AMI receiving in emergency percutaneous coronary intervention (PCI).Antiplatelet therapy in acute coronary syndromes: current agents and impact on patient outcomes.Pharmacological basis of different targets for the treatment of atherosclerosis.The 5-year projection on the future of interventional cardiology.Newer pharmacotherapy in patients undergoing percutaneous coronary interventions: a guide for pharmacists and other health care professionals.Platelet P2 receptors: old and new targets for antithrombotic drugs.Pharmacological antithrombotic adjuncts to percutaneous coronary intervention.Antiplatelet therapy in the era of drug-eluting stents: current and future perspectives.Increased incidence of in-stent thrombosis related to cocaine use: case series and review of literature.The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.Platelet interactions as therapeutic targets for prevention of atherothrombosis.Improving outcomes in patients undergoing percutaneous coronary intervention: role of prasugrel.Clopidogrel before elective percutaneous coronary intervention.Management of platelet-directed pharmacotherapy in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal procedures.Prasugrel: a critical comparison with clopidogrel.Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis.Antiplatelet therapy in acute coronary syndromes.P2Y12 antagonists in acute coronary syndrome: in whom should they be started, and when?The evolution of antiplatelet therapy in cardiovascular disease.Antiplatelet function variability in clopidogrel-treated patients: need for new antiplatelet agents.Clinical effects and outcomes with new P2Y12 inhibitors in ACS.

P2860

Q24235178-CE8AA861-60D7-4F59-A0CD-054CBF5122D1 Q28080247-D54EB5EE-03EB-4655-9200-43B6DA5E9A21 Q28167896-59214E5B-FB5A-4DE8-8B59-A8920628C966 Q28176548-6EE42366-FC2A-41DB-8708-CBFF89A757CD Q28191086-47A7CEFC-6694-42A4-9EEA-D964AACD668B Q28200177-C7FB36D4-3708-4E43-AB71-203C84174235 Q28200757-18616557-6DEC-49A6-A28F-9E8931DC8B43 Q28217724-2766D54E-23E6-407C-960D-6F7EF7C724D7 Q28218576-D199A25A-979C-4645-99AD-0E92040915F8 Q28219001-35147D47-8F52-4447-9CBB-DB8EA8BAEF31 Q28239975-C35DC87D-66C5-4DD1-9B32-12F7C99DF06E Q34580063-17E77C43-7E27-4231-9791-6144D48DF565 Q34771381-4CF63BD2-EDC3-48C7-AE3F-32E1FE948AAB Q35584070-A446BF08-00D1-488B-8FEC-72C16FBC8FB5 Q35752619-38CCA9A7-49EC-4F21-A277-8A826FB05334 Q35808289-B2B3D6AF-75D7-432E-8926-BDDB6C7C5047 Q35826523-DFB330DA-CEA7-4D6E-A9B0-F6793A38336D Q36011287-9AE6EBB1-D595-4E96-BF0C-C10021325C3A Q36040667-D8D9D783-C1C8-4BCC-978F-4CFF2DBF64C5 Q36046658-ECE3F66F-122F-42BF-A353-5AF5DBBE2CE5 Q36160606-6448F08F-3586-40D0-9DF5-B7F1511DE90F Q36346487-D3AD517F-48D7-46BB-A64B-D85914DB76F1 Q36559145-4D377BAF-BD7E-4455-A763-199B9A92C97F Q36634214-5222B8DF-0C3D-4087-B4C5-A5D0EB964785 Q36691632-E7EE2869-F5C5-4A6C-81F3-5D04CA8C9828 Q36787291-0D2A0D2F-5150-4800-AABC-BE0E84CEABC7 Q36941850-E9196A73-DF6C-4A86-A90D-8AA56635D408 Q37048954-C755B8BD-971F-4B90-B238-FCD195EC5C85 Q37380507-A287470B-0D1A-400D-9971-8406DC1043E1 Q37486621-2036346D-3A25-4AB2-B709-D424E1F7B50D Q37498604-322F187D-E480-4B91-AEE4-243F05C1D456 Q37605466-923634E0-E0A7-4D04-A5EB-279132303349 Q37638183-B587E753-5C9F-44AD-AF42-B30218FBB49F Q37641320-0297C35A-0075-4BAD-B026-AFD37000D5B8 Q37693951-AB9A0A86-F86D-4879-A9C2-8293DBDA5460 Q37798110-B6023BD0-583D-418F-939D-B40F509047DE Q37864572-47FE4151-D3C2-42D9-AE4C-B3739448B458 Q37900470-535CC2B5-A307-4337-8EEE-C2493452C83C Q37914924-BE47C787-7F48-4DC4-A743-392C2706F50D Q37927149-C45C3CDD-CB4D-4830-9ED8-92670846BA3C

P2860

Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting

http://www.wikidata.org/entity/Q28191931

description

2002 nî lūn-bûn

@nan

2002 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Meta-analysis of randomized an ...... ith clopidogrel after stenting

@ast

Meta-analysis of randomized an ...... ith clopidogrel after stenting

@en

Meta-analysis of randomized an ...... ith clopidogrel after stenting

@nl

type

label

Meta-analysis of randomized an ...... ith clopidogrel after stenting

@ast

Meta-analysis of randomized an ...... ith clopidogrel after stenting

@en

Meta-analysis of randomized an ...... ith clopidogrel after stenting

@nl

prefLabel

Meta-analysis of randomized an ...... ith clopidogrel after stenting

@ast

Meta-analysis of randomized an ...... ith clopidogrel after stenting

@en

Meta-analysis of randomized an ...... ith clopidogrel after stenting

@nl

P1433

Q28191931-B04847DD-923B-499C-B0D9-DCDA778CA921

P1476

Q28191931-56F7789A-B4AF-49F5-BBE4-26E5F372D819

P2093

Q28191931-123BA36E-FF93-42D3-913A-9F217D24BDE4

Q28191931-2618D1CD-A49B-46C2-9D63-AC1D511F664B

Q28191931-2C9B015F-9D11-4A4A-B5B7-F8BA2E0B1A69

Q28191931-5225908C-74FA-4792-8D81-7C833461362A

Q28191931-9B5379A8-3A80-4445-97A1-1135F1A48474

Q28191931-BB72D5BB-7796-466C-B89C-A79959F794AD

Q28191931-E3F479D4-75F1-421B-B9C9-920F1B5BEB0E

P304

Q28191931-2810DF20-8A96-4BE3-8C09-71F8A2021A0A

P31

Q28191931-62FC09A6-9C18-4DBE-BE11-7602B58899C4

Q28191931-C2F87288-9BB5-4634-80D4-A65662DA4BCA

P356

Q28191931-B093F3AA-B40F-4B21-AEB3-3EADF8A4DAA8

P407

Q28191931-462355D0-2AEB-49D5-A7A9-858A19B163B6

P433

Q28191931-9CA93660-3609-4B16-924B-4E1F722A3D3B

P478

Q28191931-A1766BF2-04C2-4105-82AE-10A66D5B7FAA

P50

Q28191931-216DC3D2-252B-47C2-9D73-B921F86D8A2F

Q28191931-258F4B0B-2EAE-43D0-97FB-BCE7F1D98EF9

Q28191931-3C9D7777-44CF-40A2-8663-83735F9E02A8

Q28191931-B22BCD36-5AD1-4DD6-8A01-5A6905C552C4

Q28191931-CDA21129-F702-42EC-B1A0-17E19695BC57

P577

Q28191931-2C3DF844-D77C-45AB-8BD4-9B3F29F4A023

P5875

Q28191931-0F98491A-9260-4695-950A-7AE04C6AB44C

P698

Q28191931-68DE859E-DC8D-44B9-983C-947D9C7FF9A7

P921

Q28191931-3E006440-1048-4C2B-A839-FEBA81FE9070

Q28191931-B2CC4A01-AF91-4681-9F67-CC25E0B364BC

P356

S0735-1097(01)01713-2

P1433

Journal of the American College of Cardiology

P1476

Meta-analysis of randomized an ...... ith clopidogrel after stenting

@en

P2093

David R Holmes

http://www.w3.org/2001/XMLSchema#string

Issam Moussa

http://www.w3.org/2001/XMLSchema#string

Jeffrey W Moses

http://www.w3.org/2001/XMLSchema#string

John M Lasala

http://www.w3.org/2001/XMLSchema#string

Megumi Taniuchi

http://www.w3.org/2001/XMLSchema#string

Michel E Bertrand

http://www.w3.org/2001/XMLSchema#string

Philippe L L'Allier

http://www.w3.org/2001/XMLSchema#string

P304

9-14

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0735-1097(01)01713-2

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

39

http://www.w3.org/2001/XMLSchema#string

P50

Deepak L. Bhatt

Stephen G. Ellis

George D Dangas

Peter B. Berger

P577

2002-01-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11602796

http://www.w3.org/2001/XMLSchema#string

P698

11755280

http://www.w3.org/2001/XMLSchema#string

P921